Tag Archives: oncology

Liver cancer: Roche’s Tecentriq in combination with Avastin approved by US FDA

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of care Application approved … Read the full press release

Rare disease: Enhertu of AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release

University of Zurich researchers announce novel immunotherapy against leukaemia

The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University of Zurich researchers have announced a study that is showing how hematopoietic stem cells from a healthy donor can help … Read the full press release

Brian Tyler to succeed John H. Hammergren as McKesson CEO

San Francisco, CA, USA, 05-Nov-2018 — /EuropaWire/ — McKesson Corporation (NYSE:MCK) today announced that John H. Hammergren, chairman and chief executive officer (CEO), has decided to retire, effective March 31, 2019. McKesson’s Board of Directors has unanimously selected Brian Tyler, … Read the full press release

Trinity College Dublin to launch a new, free, online course “From Diagnosis to Survivorship: An introduction to Radiation Oncology”

DUBLIN, 30-Aug-2018 — /EuropaWire/ — Trinity is launching a new, free, online course: “From Diagnosis to Survivorship: An introduction to Radiation Oncology,” from the discipline of Radiation Therapy. Starting on the 3rd of September 2018, this new free online course … Read the full press release

Novartis: the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 has met the primary endpoint

SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer … Read the full press release

Royal Philips and Singapore Institute of Advanced Medicine Holdings open Advanced Medicine Imaging (AMI) center at Biopolis research hub in Singapore

First phase of Singapore’s Advanced Medicine Imaging Center provides accurate and timely diagnosis of cancer, plus an education center for medical training and scientific research collaborations New treatment innovations, including radioisotope and proton beam therapies, will be made progressively available … Read the full press release

Novartis: Today’s FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin … Read the full press release

KTH Professor of Experimental Oncology Cecilia Williams: beta receptor’s discovery changed our understanding of estrogen signaling

STOCKHOLM, 16-Jun-2017 — /EuropaWire/ — For nearly two decades researchers have sought a way to target an estrogen receptor in the hope they could improve breast cancer survival, but an article published today in Nature Communications contends that the effort … Read the full press release

Royal Philips, Memorial Sloan Kettering Cancer Center to help improve the understanding of pancreatic cancer and advance precision oncology

Agreement aims to enable precision diagnostics for pancreatic cancer by developing new methods* to resolve single-cell level differences within and between tumors Memorial Sloan Kettering Cancer Center will use Philips IntelliSpace Genomics platform for advanced analytics and research collaboration capabilities … Read the full press release

Novartis third annual Meet Novartis Management event in Basel: Leading positions in oncology, eye care and biosimilars

Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights leading pipeline of second generation immuno-oncology assets Confirms Sandoz on track for 10 biosimilar filings by … Read the full press release

Basilea announced improved operating results in its H1-2013 financials

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release

AstraZeneca, University of Cambridge and Cancer Research UK partner on 3 pre-clinical and clinical oncology projects

16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three pre-clinical and clinical oncology projects. This agreement with world-leading medical research institutions … Read the full press release

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release